Safety and tolerability of selisistat for the treatment of huntington's disease: Results from a randomized, double-blind, placebo-controlled phase II trial

This article has no abstract
Epistemonikos ID: da7496f5b7a10cb20338d1908d9f5e1f950bc536
First added on: Feb 06, 2025